Host cell mTORC1 is required for HCV RNA replication

Gut

Volumn 65, Issue 12, 2016, Pages 2017-2028

  Stöhr, Stefanie ^a,b   Costa, Rui ^a   Sandmann, Lisa ^a,b   Westhaus, Sandra ^a,b   Pfaender, Stephanie ^c   Anggakusuma, ^c   Dazert, Eva ^d   Meuleman, Philip ^e   Vondran, Florian W R ^a,b   Manns, Michael P ^a,b   Steinmann, Eike ^c   Von Hahn, Thomas ^a,b   Ciesek, Sandra ^a,b,f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Center for Experimental and Clinical Infection Research   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Integrated Research and Treatment Center Transplantation   (Germany)

Author keywords

HEPATITIS C; LIVER TRANSPLANTATION

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; RAPAMYCIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GRAFT RECIPIENT; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS PARTICLE; VIRUS REPLICATION; DRUG EFFECTS; GENE SILENCING; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CELL; TREATMENT OUTCOME;

GENE SILENCING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER TRANSPLANTATION; MULTIPROTEIN COMPLEXES; RNA, VIRAL; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84940202073     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308971     Document Type: Article

References (40)

1. Ciesek S, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. J Viral Hepat 2012;19:1-8.
2. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011;8:69-71.
3. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013;12:595-610.
4. Delemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014;20:315-21.
5. Gurusamy KS, Tsochatzis E, Toon CD, et al. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013;12:CD006573.
6. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013;33(Suppl 1):56-62.
7. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003;9:228-35.
8. Sainz B, Chisari FV. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 2006;80:10253-7.
9. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012;26:531-48.
10. Vinaixa C, Rubin A, Aguilera V, et al. Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol 2013;26:304-13.
11. Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010;138:1875-84.
12. Gedaly R, Clifford TM, McHugh PP, et al. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int 2008;21:867-72.
13. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994;369:756-8.
14. Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol 2013;203:563-74.
15. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310-22.
16. Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, et al. Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). Cell Cycle 2011;10:3140-52.
17. Ekim B, Magnuson B, Acosta-Jaquez HA, et al. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol 2011;31:2787-801.
18. Yang H, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and regulation. Nature 2013;497:217-23.
19. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-8.
20. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
21. Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant 2014;2014:845438.
22. Nashan B. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Clin Transplant 2013;27(Suppl 25):16-29.
23. McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011;11:2379-87.
24. Asthana S, Toso C, Meeberg G, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011;25:28-34.
25. Soliman A, Fathy A, Khashab S, et al. Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidates. Exp Clin Transplant 2013;11:408-11.
26. Peng L, Liang D, Tong W, et al. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010;285:20870-81.
27. Bose SK, Meyer K, Di Bisceglie AM, et al. Hepatitis C virus induces epithelial mesenchymal transition in primary human hepatocytes. J Virol 2012;86:13621-8.
28. Bose SK, Shrivastava S, Meyer K, et al. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012;86:6315-22.
29. Burgel B, Friesland M, Koch A, et al. Hepatitis C virus enters human peripheral neuroblastoma cells-evidence for extra-hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat 2011;18:562-70.
30. Anggakusuma, Frentzen A, Gurlevik E, et al. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons. J Virol 2015;89:3833-45.
31. Kelly MA, Kaplan M, Nydam T, et al. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc 2013;45:3325-8.
32. McNulty S, Flint M, Nichol ST, et al. Host mTORC1 signaling regulates andes virus replication. J Virol 2013;87:912-22.
33. George A, Panda S, Kudmulwar D, et al. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation. J Biol Chem 2012;287:5042-58.
34. Huang H, Kang R, Wang J, et al. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. Autophagy 2013;9:175-95.
35. Ricoult SJ, Manning BD. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep 2013;14:242-51.
36. McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 2009;1791:552-9.
37. Ogawa K, Hishiki T, Shimizu Y, et al. Hepatitis C virus utilizes lipid droplet for production of infectious virus. Proc Jpn Acad Ser B Phys Biol Sci 2009;85:217-28.
38. Anderson LJ, Lin K, Compton T, et al. Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion. Virol J 2011;8:329.
39. Ishida H, Li K, Yi M, et al. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem 2007;282:11836-48.
40. Mannova P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005;79:8742-9.